Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children
© The Author(s) 2018. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
BACKGROUND: Assays to estimate human immunodeficiency virus (HIV) reservoir size require large amounts of blood, which represents a drawback especially in pediatric settings. We investigated whether HIV-antibody repertoire could estimate the viral reservoir size. Moreover, we assessed the magnitude of HIV-antibody response as a predictor of time of antiretroviral therapy (ART) initiation.
METHODS: Human immunodeficiency virus-antibody responses to 10 different viral proteins were evaluated by HIV Western blot (WB) kit and a WB score was assigned to each patient. Patients were classified in 2 subgroups based on the timing of ART initiation (early treated [ET], 0-24 weeks and late treated [LT], >24 weeks). Human immunodeficiency virus-deoxyribonucleic acid (DNA) was quantified using real-time quantitative polymerase chain reaction on total peripheral blood mononuclear cells. Logistic regression and principal component analysis were built on these data to test the ability of WB score to predict the expected value of HIV-DNA and the timing of ART initiation.
RESULTS: Sixty-nine perinatally HIV-infected children were evaluated. Reduced HIV-specific antibody responses and lower size of HIV-DNA were observed in ET compared with LT patients (P < .001 and P = .02, respectively). We found that WB score correlates with HIV-DNA (P = .032) and timing of ART initiation (P < .001). Based on the logistic regression analysis, we found that WB score can predict the HIV-DNA size and the timing of ART initiation with an Akaike information criterion of -118.13 and -151.51, respectively.
CONCLUSIONS: Western blot score can estimate HIV-DNA size and timing of ART initiation in long-term virally suppressed children. This rapid, inexpensive, and easily reproducible tool can provide useful information to identify potential candidates for HIV remission studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of the Pediatric Infectious Diseases Society - 8(2019), 5 vom: 06. Nov., Seite 433-438 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rocca, Salvatore [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-HIV Agents |
|---|
| Anmerkungen: |
Date Completed 30.03.2020 Date Revised 27.07.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jpids/piy080 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM288075935 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM288075935 | ||
| 003 | DE-627 | ||
| 005 | 20231225055445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jpids/piy080 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0960.xml |
| 035 | |a (DE-627)NLM288075935 | ||
| 035 | |a (NLM)30169837 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rocca, Salvatore |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.2020 | ||
| 500 | |a Date Revised 27.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2018. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Assays to estimate human immunodeficiency virus (HIV) reservoir size require large amounts of blood, which represents a drawback especially in pediatric settings. We investigated whether HIV-antibody repertoire could estimate the viral reservoir size. Moreover, we assessed the magnitude of HIV-antibody response as a predictor of time of antiretroviral therapy (ART) initiation | ||
| 520 | |a METHODS: Human immunodeficiency virus-antibody responses to 10 different viral proteins were evaluated by HIV Western blot (WB) kit and a WB score was assigned to each patient. Patients were classified in 2 subgroups based on the timing of ART initiation (early treated [ET], 0-24 weeks and late treated [LT], >24 weeks). Human immunodeficiency virus-deoxyribonucleic acid (DNA) was quantified using real-time quantitative polymerase chain reaction on total peripheral blood mononuclear cells. Logistic regression and principal component analysis were built on these data to test the ability of WB score to predict the expected value of HIV-DNA and the timing of ART initiation | ||
| 520 | |a RESULTS: Sixty-nine perinatally HIV-infected children were evaluated. Reduced HIV-specific antibody responses and lower size of HIV-DNA were observed in ET compared with LT patients (P < .001 and P = .02, respectively). We found that WB score correlates with HIV-DNA (P = .032) and timing of ART initiation (P < .001). Based on the logistic regression analysis, we found that WB score can predict the HIV-DNA size and the timing of ART initiation with an Akaike information criterion of -118.13 and -151.51, respectively | ||
| 520 | |a CONCLUSIONS: Western blot score can estimate HIV-DNA size and timing of ART initiation in long-term virally suppressed children. This rapid, inexpensive, and easily reproducible tool can provide useful information to identify potential candidates for HIV remission studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HIV reservoir | |
| 650 | 4 | |a HIV-antibody repertoire | |
| 650 | 4 | |a children | |
| 650 | 4 | |a early antiretroviral therapy | |
| 650 | 4 | |a serology | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 650 | 7 | |a HIV Antibodies |2 NLM | |
| 700 | 1 | |a Zangari, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Cotugno, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a De Rossi, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Ferns, Bridget |e verfasserin |4 aut | |
| 700 | 1 | |a Petricone, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Rinaldi, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Giaquinto, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Bernardi, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Rojo, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Pahwa, Savita |e verfasserin |4 aut | |
| 700 | 1 | |a Nastouli, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Palma, Paolo |e verfasserin |4 aut | |
| 700 | 0 | |a EPIICAL Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Nigel |e investigator |4 oth | |
| 700 | 1 | |a Gibb, Diana |e investigator |4 oth | |
| 700 | 1 | |a Watters, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Chan, Man |e investigator |4 oth | |
| 700 | 1 | |a McCoy, Laura |e investigator |4 oth | |
| 700 | 1 | |a Babiker, Abdel |e investigator |4 oth | |
| 700 | 1 | |a Marcelin, Anne-Genevieve |e investigator |4 oth | |
| 700 | 1 | |a Calvez, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Munoz, Maria Angeles |e investigator |4 oth | |
| 700 | 1 | |a Wahren, Britta |e investigator |4 oth | |
| 700 | 1 | |a Foster, Caroline |e investigator |4 oth | |
| 700 | 1 | |a Cotton, Mark |e investigator |4 oth | |
| 700 | 1 | |a Robb, Merlin |e investigator |4 oth | |
| 700 | 1 | |a Ananworanich, Jintanat |e investigator |4 oth | |
| 700 | 1 | |a Claiden, Polly |e investigator |4 oth | |
| 700 | 1 | |a Pillay, Deenan |e investigator |4 oth | |
| 700 | 1 | |a Persaud, Deborah |e investigator |4 oth | |
| 700 | 1 | |a De Boer, Rob J |e investigator |4 oth | |
| 700 | 1 | |a Schröter, Juliane |e investigator |4 oth | |
| 700 | 1 | |a Anelone, Anet J N |e investigator |4 oth | |
| 700 | 1 | |a Puthanakit, Thanyawee |e investigator |4 oth | |
| 700 | 1 | |a Ceci, Adriana |e investigator |4 oth | |
| 700 | 1 | |a Giannuzzi, Viviana |e investigator |4 oth | |
| 700 | 1 | |a Luzuriaga, Kathrine |e investigator |4 oth | |
| 700 | 1 | |a Chomont, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Cameron, Mark |e investigator |4 oth | |
| 700 | 1 | |a Cancrini, Caterina |e investigator |4 oth | |
| 700 | 1 | |a Yates, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Kuhn, Louise |e investigator |4 oth | |
| 700 | 1 | |a Violari, Avy |e investigator |4 oth | |
| 700 | 1 | |a Otwombe, Kennedy |e investigator |4 oth | |
| 700 | 1 | |a Pepponi, Ilaria |e investigator |4 oth | |
| 700 | 1 | |a Rocchi, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Rinaldi, Stefano |e investigator |4 oth | |
| 700 | 1 | |a Tagarro, Alfredo |e investigator |4 oth | |
| 700 | 1 | |a Lain, Maria Grazia |e investigator |4 oth | |
| 700 | 1 | |a Vaz, Paula |e investigator |4 oth | |
| 700 | 1 | |a Lopez, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Nhampossa, Tacita |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the Pediatric Infectious Diseases Society |d 2012 |g 8(2019), 5 vom: 06. Nov., Seite 433-438 |w (DE-627)NLM227436326 |x 2048-7207 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2019 |g number:5 |g day:06 |g month:11 |g pages:433-438 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jpids/piy080 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2019 |e 5 |b 06 |c 11 |h 433-438 | ||